Delirium is a condition of acute disturbance in attention and awareness along with disturbances in cognition. It is a symptom of deranged homeostasis and an early sign of infection or hypoxia. The occurrence of COVID-19 brought a catastrophic reduction in delirium monitoring, prevention, and patient care due to several organizational issues like lack of personnel, increased use of benzodiazepines and restricted family visitation.
For the future development of an ideal intensive care unit (ICU) it is important to make the patients free from delirium. As delirium is associated with worse ICU-related outcomes and long-term cognitive impairment in critical illnesses.
Screening for delirium requires limited time and effort. Completing good sedation practices by novel ICU design and connectivity will facilitate non-pharmacological sedation, anxiolysis and comfort which can further be supplemented by balanced pharmacological interventions when necessary. Improvements in the ICU sound, light control, floor planning, and room arrangement can also facilitate a healing environment which would eventually minimize stressors and aid delirium prevention and management.
The fundamental prerequisite to realize the delirium-free ICU, is an awake non-sedated, pain-free comfortable patient whose management follows the A to F (A–F) bundle. Moreover, gaining (G) insight into patient needs, delivering holistic care with a ‘home-like’ (H) environment, and redefining ICU architectural design (I).
The most important thing is to obtain a delirium-free world. It requires optimization of design of ICU, environmental factors, management, time spent with the patient and family by the criticare teams during their routine ICU care.
Read more such content on Hidoc Dr | Medical Learning App for Doctors
1.
According to the CAPTIVATE Study, fixed-duration ibrutinib plus venetoclax may be beneficial for patients with high-risk chronic lymphocytic leukemia.
2.
Scientists develop novel adjuvant delivery system to enhance cancer vaccine effectiveness
3.
Vepdegestrant Earns FDA Nod for ESR1-Mutated Breast Cancer
4.
According to a study, taking part in a clinical trial for cancer may not actually increase survival.
5.
A new blood test greatly increases the ability to detect cancer.
1.
Cancer Memory: A Persistent Threat to Tumor Recurrence and Metastasis
2.
Unraveling the Mysteries of Hematocrit: How It Impacts Your Health
3.
The Transformative Power of Genomics in the Diagnosis and Management of Rare Cancers
4.
Omega-3 Fatty Acids as Molecular Adjuvants Against Chemoresistance in Breast Cancer
5.
Surprising Symptoms of Prostate Cancer: What You Need to Know
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part X
2.
Efficient Management of First line ALK-rearranged NSCLC - Part III
3.
What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?
4.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
5.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation